Haemonetics Corporation Financial Statements (HAE)
|
|
|
|
Report date
|
|
|
25.05.2022 |
22.05.2023 |
20.05.2024 |
21.05.2025 |
20.05.2026 |
|
20.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
993.2 |
1 169 |
1 309 |
1 361 |
1 334 |
|
1 334 |
|
Operating Income, bln rub |
|
|
80.8 |
156.0 |
164.9 |
221.8 |
241.4 |
|
242.2 |
|
EBITDA, bln rub |
? |
|
191.7 |
252.0 |
295.5 |
356.0 |
397.1 |
|
337.6 |
|
Net profit, bln rub |
? |
|
43.4 |
115.4 |
117.6 |
167.7 |
97.3 |
|
97.3 |
|
|
OCF, bln rub |
? |
|
172.3 |
273.1 |
181.8 |
181.7 |
293.2 |
|
293.2 |
|
CAPEX, bln rub |
? |
|
96.5 |
110.2 |
66.3 |
39.3 |
32.8 |
|
32.8 |
|
FCF, bln rub |
? |
|
75.8 |
162.9 |
115.5 |
142.4 |
260.4 |
|
260.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
|
|
|
|
|
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
450.0 |
466.8 |
547.0 |
556.7 |
502.2 |
|
522.7 |
|
Cost of production, bln rub |
|
|
462.4 |
545.8 |
597.1 |
582.3 |
590.4 |
|
569.1 |
|
R&D, bln rub |
|
|
55.2 |
58.6 |
63.0 |
69.4 |
59.8 |
|
59.5 |
|
Interest expenses, bln rub |
|
|
17.1 |
14.6 |
13.0 |
9.75 |
28.7 |
|
24.8 |
|
|
Assets, bln rub |
|
|
1 860 |
1 935 |
2 196 |
2 451 |
2 396 |
|
2 396 |
|
Net Assets, bln rub |
? |
|
749.4 |
818.0 |
960.0 |
820.8 |
796.3 |
|
796.3 |
|
Debt, bln rub |
|
|
780.8 |
765.9 |
807.8 |
1 225 |
1 225 |
|
1 225 |
|
Cash, bln rub |
|
|
259.5 |
284.5 |
178.8 |
306.8 |
245.4 |
|
245.4 |
|
Net debt, bln rub |
|
|
521.3 |
481.4 |
629.0 |
918.0 |
979.1 |
|
979.1 |
|
|
Ordinary share price, rub |
|
|
63.2 |
82.8 |
|
|
|
|
|
|
Number of ordinary shares, mln |
|
|
51.0 |
50.8 |
50.7 |
50.3 |
47.2 |
|
46.2 |
|
|
Market cap, bln rub |
|
|
3 227 |
4 202 |
0 |
0 |
0 |
|
0 |
|
EV, bln rub |
? |
|
3 748 |
4 684 |
629 |
918 |
979 |
|
979 |
|
Book value, bln rub |
|
|
-28 |
76 |
-11 |
-239 |
-308 |
|
-308 |
|
|
EPS, rub |
? |
|
0.85 |
2.27 |
2.32 |
3.33 |
2.06 |
|
2.11 |
|
FCF/share, rub |
|
|
1.48 |
3.21 |
2.28 |
2.83 |
5.52 |
|
5.63 |
|
BV/share, rub |
|
|
-0.55 |
1.50 |
-0.22 |
-4.75 |
-6.52 |
|
-6.66 |
|
|
EBITDA margin, % |
? |
|
19.3% |
21.6% |
22.6% |
26.2% |
29.8% |
|
25.3% |
|
Net margin, % |
? |
|
4.37% |
9.87% |
8.98% |
12.3% |
7.29% |
|
7.29% |
|
FCF yield, % |
? |
|
2.35% |
3.88% |
|
|
|
|
|
|
ROE, % |
? |
|
5.79% |
14.1% |
12.2% |
20.4% |
12.2% |
|
12.2% |
|
ROA, % |
? |
|
2.33% |
5.96% |
5.35% |
6.84% |
4.06% |
|
4.06% |
|
|
P/E |
? |
|
74.4 |
36.4 |
0.00 |
0.00 |
0.00 |
|
0.00 |
|
P/FCF |
|
|
42.6 |
25.8 |
0.00 |
0.00 |
0.00 |
|
0.00 |
|
P/S |
? |
|
3.25 |
3.60 |
0.00 |
0.00 |
0.00 |
|
0.00 |
|
P/BV |
? |
|
-114.7 |
55.3 |
0.00 |
0.00 |
0.00 |
|
0.00 |
|
EV/EBITDA |
? |
|
19.6 |
18.6 |
2.13 |
2.58 |
2.47 |
|
2.90 |
|
Debt/EBITDA |
|
|
2.72 |
1.91 |
2.13 |
2.58 |
2.47 |
|
2.90 |
|
|
R&D/CAPEX, % |
|
|
57.2% |
53.2% |
95.1% |
176.7% |
182.3% |
|
181.6% |
|
|
CAPEX/Revenue, % |
|
|
9.72% |
9.43% |
5.06% |
2.89% |
2.46% |
|
2.46% |
|
| Haemonetics Corporation shareholders |
